Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30505689 | 0.85 | CYP2C9 (0.50) | CYP2C9SMN1; SMN2LMNAHPGDTAAR1 | |
| SCHEMBL21622792 | 0.82 | TAAR1 (0.48) | DRD2DRD4DRD3ALDH1A1PNMT | |
| SCHEMBL24105617 | 0.80 | L3MBTL1 (0.42) | ABL1DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL27795329 | 0.80 | CYP2C9 (0.44) | CYP2C9SMN1; SMN2LMNAHPGDTAAR1 | |
| SCHEMBL4863794 | 0.79 | NPC1 (0.57) | ABL1ALDH1A1CYP2C9IDO1SMN1; SMN2 | |
| SCHEMBL11314534 | 0.78 | L3MBTL1 (0.46) | DRD2DRD4DRD3ALDH1A1CYP2C9 | |
| SCHEMBL11639244 | 0.78 | CYP3A4 (0.59) | ALDH1A1CYP2C9SMN1; SMN2LMNAHPGD | |
| SCHEMBL7073867 | 0.78 | DRD2 (0.43) | DRD2DRD4DRD3ALDH1A1SMN1; SMN2 | |
| SCHEMBL10385967 | 0.76 | CYP2C9 (0.44) | CYP2C9SMN1; SMN2LMNAHPGDTAAR1 | |
| SCHEMBL9024874 | 0.76 | HPGD (0.54) | ABL1DRD4DRD3CYP2C9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117019156-A | Supported metal cluster catalyst and preparation method thereof | 南京大学 | 2023-11-10 | — | — | CN | claimed |
| CN-116789579-A | Preparation method of ultrafast metal-free solvent-free disulfide bond-containing compound | 南京工业大学 | 2023-09-22 | — | — | CN | claimed |
| CN-114477223-B | Preparation method and application of sulfhydryl-functionalized SBA molecular sieve | 中国石油化工股份有限公司 | 2023-09-08 | — | — | CN | claimed |
| CN-114477223-B | Preparation method and application of sulfhydryl-functionalized SBA molecular sieve | 中国石油化工股份有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-114105167-B | Sulfhydryl functional MCM-41 molecular sieve and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-114751936-A | Method for phosphorylation of amine, amide, alcohol and mercaptan | 河南大学 | 2022-07-15 | — | — | CN | disclosed |
| CN-110514823-A | A kind of blood platelet inhibiting rate detection kit and preparation method thereof and detection method | MEDCAPTAIN MEDICAL TECH CO LTD | 2019-11-29 | — | — | CN | disclosed |
| CN-107108662-A | Silylation of aromatic heterocycles by earth-rich transition metal-free catalysts | 加州理工学院 | 2017-08-29 | — | — | CN | disclosed |
| CN-105418610-B | A kind of 10 hydroxyevodiamine anti-tumor compounds and its preparation method and application | 中国人民解放军第二军医大学 | 2017-07-28 | — | — | CN | disclosed |
| US-8410161-B2 | Thioxanthone ring system derivatives | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2013-04-02 | — | — | US | disclosed |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-5874424-A | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-02-23 | — | — | US | disclosed |
| US-5847135-A | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-12-08 | — | — | US | disclosed |
| EP-0869967-A2 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5716929-A | THERAPY FOR INFLAMMATION, AUTOIMMUNE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0784628-A1 | INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | Vertex Pharmaceuticals Incorporated (US) | 1997-07-23 | — | — | EP | disclosed |
| WO-1997022619-A2 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-06-26 | — | — | WO | disclosed |
| WO-1995035308-A1 | INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1995-12-28 | — | — | WO | disclosed |
| US-4432992-A | PREVENTION OF CALCIUM OXALATE KIDNEY OR BLADDER STONES | MERCK & CO., INC. (US) | 1984-02-21 | — | — | US | disclosed |
| US-4375474-A | BACTERICIDES, FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1983-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | ABL1 3975/4885DRD2 4878/4885DRD4 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.